demonstrated the therapeutic potential of dual inhibition targeting MET and EGFR through the use of MET inhibitors (crizotinib and tepotinib) and EGFR–MET bispecific antibodies (EMB‐01 and amivantamab) in treating drug‐resistant METex14‐driven EGFR lung cancer. This evidence concerns the gene MET and lung carcinoma.